AstraZeneca plc’s Neutral Rating Reaffirmed at Bryan Garnier & Cie (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reaffirmed by equities researchers at Bryan Garnier & Cie in a research report issued on Thursday. They currently have a GBX 4,400 ($72.81) price objective on the stock. Bryan Garnier & Cie’s price target suggests a potential downside of 1.10% from the stock’s previous close.
AZN has been the subject of a number of other recent research reports. Analysts at Panmure Gordon reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Friday, August 22nd. They now have a GBX 4,400 ($72.81) price target on the stock. Separately, analysts at Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, August 21st. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, August 21st. They now have a GBX 4,000 ($66.19) price target on the stock. Six analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of GBX 4,062.28 ($67.22).
Shares of AstraZeneca plc (LON:AZN) opened at 4441.2881 on Thursday. AstraZeneca plc has a 1-year low of GBX 3086.50 and a 1-year high of GBX 5750.00. The stock’s 50-day moving average is GBX 4314.16 and its 200-day moving average is GBX 4226.77. The company’s market cap is £56.093 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.